A Phase 4, Multicenter, Randomized, Placebo-controlled, Double-blind, Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate Plaque Psoriasis
Phase of Trial: Phase IV
Latest Information Update: 15 Dec 2017
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms UNVEIL
- Sponsors Celgene Corporation
- 09 May 2017 Status changed from active, no longer recruiting to completed.
- 05 Mar 2017 Results presented at the American Academy of Dermatology's Annual Meeting 2017, according to a Celgene Corporation media release.
- 05 Mar 2017 Results published in a Celgene Corporation media release.